{"id":212589,"date":"2026-05-12T09:16:00","date_gmt":"2026-05-12T13:16:00","guid":{"rendered":"https:\/\/testing.news-you-need.com\/index.php\/2026\/05\/12\/insilico-medicine-and-ribo-enter-strategic-collaboration-agreement-leveraging-ai-platform-and-automated-lab-for-end-to-end-empowerment-of-rna-interference-and-oligonucleotide-therapeutics-development\/"},"modified":"2026-05-12T09:20:10","modified_gmt":"2026-05-12T13:20:10","slug":"insilico-medicine-and-ribo-enter-strategic-collaboration-agreement-leveraging-ai-platform-and-automated-lab-for-end-to-end-empowerment-of-rna-interference-and-oligonucleotide-therapeutics-development","status":"publish","type":"post","link":"https:\/\/testing.news-you-need.com\/index.php\/2026\/05\/12\/insilico-medicine-and-ribo-enter-strategic-collaboration-agreement-leveraging-ai-platform-and-automated-lab-for-end-to-end-empowerment-of-rna-interference-and-oligonucleotide-therapeutics-development\/","title":{"rendered":"Insilico Medicine and Ribo enter strategic collaboration agreement: Leveraging AI platform and automated lab for end-to-end empowerment of RNA interference and oligonucleotide therapeutics development"},"content":{"rendered":"<p><a href=\"https:\/\/www.eurekalert.org\/news-releases\/1127637\">Insilico Medicine and Ribo enter strategic collaboration agreement: Leveraging AI platform and automated lab for end-to-end empowerment of RNA interference and oligonucleotide therapeutics development<\/a><\/p>\n<p><a href=\"https:\/\/www.eurekalert.org\/news-releases\/1127637\">https:\/\/www.eurekalert.org\/news-releases\/1127637<\/a><\/p>\n<p>Publish Date: <a href=\"publish_date]\">2026-05-12 09:16:00<\/a><\/p>\n<p>Source Domain: <a href=\"www.eurekalert.org\">www.eurekalert.org<\/a><\/p>\n<ul>\n<li><strong>Strategic Collaboration Announcement<\/strong>: Insilico Medicine and Suzhou Ribo Life Science Co. have announced a strategic collaboration aimed at boosting oligonucleotide drug research and development efficiency.<\/li>\n<li><strong>Integration of Technologies<\/strong>: The collaboration leverages Insilico&#8217;s advanced Pharma.AI platform and Ribo&#8217;s expertise in oligonucleotide therapeutics development, enhancing the overall research and development process.<\/li>\n<li><strong>Enhanced Efficiency in R&amp;D Cycle<\/strong>: The partnership aims to significantly speed up and improve the oligonucleotide drug research and development cycle through the combination of AI-driven insights and Ribo&#8217;s extensive technological platforms.<\/li>\n<li><strong>First Partner for LifeStar 2 Lab<\/strong>: Ribo has been designated as the first partner for high-throughput experimental services utilizing Insilico&#8217;s LifeStar 2 automated laboratory platform, highlighting the industrial significance of this collaboration.<\/li>\n<li><strong>Focus on Global Health Benefits<\/strong>: Both companies emphasize the potential global impact of the collaboration, aiming to develop AI-driven oligonucleotide therapies to benefit humanity by addressing unmet clinical needs.<\/li>\n<\/ul>\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Insilico Medicine and Ribo enter strategic collaboration agreement: Leveraging AI platform and automated lab for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":212590,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/mediasvc.eurekalert.org\/Api\/v1\/Multimedia\/e79f02a1-4409-44b1-8741-b7de439f5a4d\/Rendition\/thumbnail\/Content\/Public","fifu_image_alt":"","footnotes":""},"categories":[14],"tags":[],"class_list":["post-212589","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-artificial-intelligence"],"_links":{"self":[{"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/212589"}],"collection":[{"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/comments?post=212589"}],"version-history":[{"count":1,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/212589\/revisions"}],"predecessor-version":[{"id":212591,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/212589\/revisions\/212591"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/media\/212590"}],"wp:attachment":[{"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/media?parent=212589"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/categories?post=212589"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/tags?post=212589"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}